Literature DB >> 2858227

Multidimensional analysis of the concentrations of 17 substances in the CSF of schizophrenics and controls.

W F Gattaz, T Gasser, H Beckmann.   

Abstract

The concentrations of 17 substances were determined in the cerebrospinal fluid (CSF) of 28 paranoid schizophrenic patients and 16 controls. Results were standardized and simultaneously evaluated through Multidimensional Scaling (MDS). The full data set can be considered as a cloud of points consisting of the 44 subjects in the 17-dimensional parameter space. MDS seeks a two-dimensional representation of this 17-dimensional cloud of points, while retaining as much as possible the distances between the subjects. The two-dimensional reduction of the 17 CSF parameters correctly separated 15 of 16 controls from the schizophrenic subjects. This indicates that a biological heterogeneity between schizophrenic and nonschizophrenic subjects can be detected by the simultaneous analysis of the CSF concentrations of substances related directly or indirectly to the neuronal activity in the brain.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2858227     DOI: 10.1016/0006-3223(85)90038-1

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  10 in total

Review 1.  Recent advances in targeting the ionotropic glutamate receptors in treating schizophrenia.

Authors:  Robert E McCullumsmith; John Hammond; Adam Funk; James H Meador-Woodruff
Journal:  Curr Pharm Biotechnol       Date:  2012-06       Impact factor: 2.837

2.  Abnormal expression of glutamate transporter and transporter interacting molecules in prefrontal cortex in elderly patients with schizophrenia.

Authors:  Deborah Bauer; Daya Gupta; Vahram Harotunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Schizophr Res       Date:  2008-08-03       Impact factor: 4.939

Review 3.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

Review 4.  The phenolic interactome and gut microbiota: opportunities and challenges in developing applications for schizophrenia and autism.

Authors:  George E Jaskiw; Mark E Obrenovich; Curtis J Donskey
Journal:  Psychopharmacology (Berl)       Date:  2019-06-13       Impact factor: 4.530

5.  Cerebrospinal fluid glutamate concentration correlates with impulsive aggression in human subjects.

Authors:  Emil F Coccaro; Royce Lee; Paul Vezina
Journal:  J Psychiatr Res       Date:  2013-06-18       Impact factor: 4.791

Review 6.  Possible mechanisms of neurodegeneration in schizophrenia.

Authors:  Iván Pérez-Neri; Jesús Ramírez-Bermúdez; Sergio Montes; Camilo Ríos
Journal:  Neurochem Res       Date:  2006-09-28       Impact factor: 3.996

7.  Cerebrospinal fluid catecholamine levels as predictors of outcome in subarachnoid hemorrhage.

Authors:  Michael Moussouttas; Thanh T Huynh; John Khoury; Edwin W Lai; Keith Dombrowski; Scott Pello; Karel Pacak
Journal:  Cerebrovasc Dis       Date:  2012-01-05       Impact factor: 2.762

Review 8.  Clinical investigation of monoamine neurotransmitter interactions.

Authors:  J K Hsiao; W Z Potter; H Agren; R R Owen; D Pickar
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

9.  Evidence for biochemical heterogeneity in schizophrenia: a multivariate study of monoaminergic indices in human post-mortal brain tissue.

Authors:  L O Hansson; N Waters; B Winblad; C G Gottfries; A Carlsson
Journal:  J Neural Transm Gen Sect       Date:  1994

10.  Dopamine and glutamate in schizophrenia: biology, symptoms and treatment.

Authors:  Robert A McCutcheon; John H Krystal; Oliver D Howes
Journal:  World Psychiatry       Date:  2020-02       Impact factor: 49.548

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.